Last reviewed · How we verify
FOSLEVODOPA — Competitive Intelligence Brief
marketed
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
FOSLEVODOPA (FOSLEVODOPA) — AbbVie GK. Foslevodopa works by increasing the levels of levodopa in the brain, which helps to alleviate symptoms of Parkinson's disease.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| FOSLEVODOPA TARGET | FOSLEVODOPA | AbbVie GK | marketed | 2024-01-01 |
Recent regulatory actions (last 90 days)
- — FOSLEVODOPA · FDA · approved · US · AbbVie GK
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- FOSLEVODOPA CI watch — RSS
- FOSLEVODOPA CI watch — Atom
- FOSLEVODOPA CI watch — JSON
- FOSLEVODOPA alone — RSS
Cite this brief
Drug Landscape (2026). FOSLEVODOPA — Competitive Intelligence Brief. https://druglandscape.com/ci/foslevodopa. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab